SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH M impact

FDA grants priority review to Insmed's ARIKAYCE for MAC lung disease

FDA accepted Insmed's supplemental New Drug Application (sNDA) for ARIKAYCE in MAC lung disease as part of combination therapy, granting Priority Review. The Prescription Drug User Fee Act (PDUFA) target action date is set for Jan. 28, 2027. The filing seeks full approval, supported by Phase 3b ENCORE results.

INSM.O

Story updates

12:27:55 PM UTC
SquawkNews
Sept 21 (Reuters) — Insmed Incorporated: Fda Grants Priority Review To Insmed's Snda For Arikayce® (Amikacin Liposome Inhalation Suspension) For Treatment Of Mac Lung Disease With Pdufa Target Action Date Set For January 28, 2027 Source text:... Further company coverage: INSM.O (Reuters.Briefs@thomsonreuters.com;)

Related stories